Agios Pharmaceuticals, Inc. (AGIO) is a development-stage biopharmaceutical company with a focus on the development of a potential treatment for cancer and rare genetic disorders of metabolism. This Cambridge, MA-based company has three candidates in its pipeline, namely, AG-221 (IDH2 mutant inhibitor – advanced hematologic malignancies like acute myelogenous leukemia/AML and solid tumors), AG-120 (IDH1 mutant inhibitor – AML and solid tumors) and AG-348 (pyruvate kinase deficiency).
Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-120.
With Agios not having any approved products in its portfolio, investor focus should remain on pipeline updates since a number of pipeline related activities are lined up for the rest of 2015.
Agios has a disappointing earnings track record with the company delivering negative earnings surprises in three of the last four trailing quarters. However, the company has a positive average surprise of 15.10%. Estimate revisions are, however, flat for 2015.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agios posted narrower-than-expected first quarter loss. Our consensus called for a loss of 89 cents per share, and the company reported a loss of 13 cents per share.
Revenue: Revenues also surpassed expectations. Agios posted revenues of $14.6 million, compared to our consensus estimate of $10 million.
Key Stats: Agios continues to progress with its pipeline. The company also plans to initiate combination studies on AG-221 for the treatment for patients with AML and a broad range of hematologic malignancies in the second half of 2015. The company also has plans to initiate a phase III study on the candidate in relapsed/refractory AML patients in the second half of 2015. Agios also has initiate three expansion cohorts as part of an ongoing phase I study on AG-120 (hematologic malignancies) and intends to present first data from the phase I trial on AG-120 in the advanced solid tumors indication in the second half of 2015.